Cartalax 20 mg

Steroids Dragon Pharma Peptides

$70.00

Dragon Pharma Cartalax 20 mg – Synthetic Tripeptide for Cartilage and Joint Research

✔ Synthetic AED tripeptide bioregulator ✔ Peptide bioregulator for connective tissue ✔ Studied for cartilage and joint support ✔ USA domestic shipping available

Dragon Pharma Cartalax 20 mg is a synthetic short tripeptide with the amino acid sequence Ala-Glu-Asp (AED). Classified as a peptide bioregulator, this compound has been studied preclinically for its potential to support cartilage, joint health, and connective tissue maintenance by influencing gene expression in chondrocytes and other joint-related cells.

Each vial contains 20 mg of lyophilized Cartalax in a 2 mL format, requiring reconstitution with bacteriostatic water before use. Cartalax represents a targeted research tool for investigating the molecular mechanisms underlying cartilage maintenance, chondrocyte function, and the biological processes involved in joint health. For related research compounds, explore our peptides category and specifically BPC 157 for complementary tissue repair research applications.

What Makes Cartalax Valuable in Research?

Cartalax belongs to a class of short-chain peptides known for their tissue-specific bioregulatory properties. The AED sequence has been studied for its ability to influence cellular processes relevant to cartilage and joint biology, including the regulation of gene expression in chondrocytes and the modulation of connective tissue metabolism. Its defined sequence and mechanism of action make it a practical tool for investigating the molecular basis of cartilage maintenance and joint function.

Researchers value Cartalax for its targeted approach to studying cartilage and connective tissue biology. Its ability to influence chondrocyte gene expression provides insights into the mechanisms that govern cartilage health and age-related changes in joint tissues. For investigators exploring other aspects of connective tissue research, TB 500 offers complementary research avenues in tissue repair and regeneration.

Current scientific literature on peptide bioregulators can be accessed through the PubMed database, where researchers can review peer-reviewed studies on related compounds and experimental applications.

Key Research Applications for Dragon Pharma Cartalax

✔ Investigation of chondrocyte gene expression and function
✔ Evaluation of cartilage maintenance and metabolism
✔ Research on connective tissue regulation and repair
✔ Studies of joint health and age-related changes
✔ Preclinical models of cartilage biology and joint function

For Research Purposes Only

Cartalax 20 mg is intended for research use only and is not approved for human consumption. Proper handling, reconstitution, and experimental protocols are essential for reliable results. For studies on wound healing and tissue repair, GHK-CU 50 mg provides additional research avenues in connective tissue regeneration.

Dispatched within 24 hours in plain, discreet packaging.

Additional Information

Categories:

Steroids

Brand: Dragon Pharma

Manufacturer: Dragon Pharma

Dosage Info: <div class="tab-pane fade" id="offer-tabbody--dosage-and-usage" role="tabpanel"> <section class="tab-panel" id="panel-usage"> <h2>Dosage & Usage Guidelines</h2> <div class="info-card warning"> <p><strong>For research and laboratory use only.</strong> Dragon Pharma Cartalax 20 mg is a synthetic tripeptide bioregulator. Proper reconstitution, handling, and experimental design are essential for obtaining reliable data.</p> </div> <h3>Reconstitution Protocol</h3> <ul class="usage-highlights"> <li>✔ Use sterile bacteriostatic water for injection</li> <li>✔ Add appropriate volume to achieve desired concentration</li> <li>✔ Swirl gently to dissolve – do not shake vigorously</li> <li>✔ Store reconstituted solution at 2–8°C</li> </ul> <p>Reconstitute the lyophilized powder using bacteriostatic water to a concentration suitable for your research protocol. The 20 mg format allows for flexible dosing across a range of experimental models. Always use aseptic technique during preparation to maintain peptide integrity.</p> <h3>Typical Research Parameters</h3> <p>In research settings, Cartalax is typically administered via subcutaneous injection. Dosing schedules and concentrations vary widely depending on the experimental design, animal model, and specific research objectives.</p> <ul> <li>✔ Commonly used in cartilage and joint studies</li> <li>✔ Often combined with histological and molecular analysis</li> <li>✔ Used to investigate chondrocyte gene expression</li> <li>✔ Research models include cartilage maintenance and joint health paradigms</li> </ul> <h3>Factors to Consider in Research Protocols</h3> <ul> <li>Short-chain peptide with specific bioregulatory properties</li> <li>Reconstitution stability is limited; prepare fresh solutions for each use</li> <li>Individual variation in response may be observed across subjects</li> <li>Storage conditions significantly impact peptide stability</li> </ul> <div class="info-card"> <p><strong>Research note:</strong> Cartalax is a peptide bioregulator with the AED sequence, studied for its potential effects on cartilage and connective tissue. Its mechanism of action involves influencing gene expression in chondrocytes and other cells involved in joint maintenance, making it a valuable tool for investigating cartilage biology and age-related changes in joint tissues.</p> </div> </section> </div>

Reviews:

(0 customer reviews)